INSM (Insmed Inc) Market Value to Book Value Ratio

Insmed Inc (INSM) - corporate logo

Insmed Incorporated (INSM) transition from laboratory research to the global commercialization of drugs drives the dynamics of its price-to-book ratio. High medical authority and the uniqueness of its therapies for rare lung pathologies create a steady cash generator. The value 27.28 represents the current level of this metric, demonstrating the gap between market expectations and the company's actual net assets.

Market Capitalization to Net Assets: Insmed Corp (INSM) for 07/04/2022 - 10/28/2026
Finished products of Insmed Inc.

This indicator separates the fundamental value of net assets from price volatility by measuring the market premium over book capital. Analyzing the ratio of market capitalization to book value allows for an assessment of asset overheating, while a high premium for Insmed Incorporated (INSM) confirms the value of its intellectual capital and the commitment of leading rare disease researchers to the company's mission.

Direct competitors

VRTX (Vertex Pharmaceuticals) - Market Value to Book Value Ratio|ALNY (alnylam.com) - Market Cap to Net Assets Ratio|UTHR: Market Value to Book Value Ratio|Market Capitalization to Book Value BMRN|BBIO - Market Value to Book Value Ratio|Market Capitalization to Net Assets bgm.ltd (BGM)|COGT: Market Capitalization to Book Value Ratio|Market-to-Book Ratio xerispharma.com XERS|KROS: Market Capitalization to Book Value Ratio|ARCT - Market Cap to Net Assets Ratio|Eton Pharma - Market Capitalization to Book Value Ratio|Kamada Pharma (KMDA) - Market Capitalization to Book Value|FULC (Fulcrum Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ABEO|Market Value to Book Value Ratio Mereo BioPharma (MREO)|Market Value to Book Value Ratio Protalix BioTherapeutics Inc. (PLX)|Market Capitalization to Book Value Ratio PLRX|APLT - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Rein Therapeutics Inc|GELS - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio AYTU|Chemomab Therapeutics Ltd. (CMMB) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio SRx Health Solutions Inc (SRXH)|Capitalization to Book Value Ratio Polyrizon Ltd. (PLRZ)|Aeterna Zentaris (AEZS) - Market Cap to Net Assets Ratio|Market Value to Book Value CYTH (cyclotherapeutics.com)|Inozyme Pharma (INZY) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Reneo Pharmaceuticals Inc. RPHM|Market Capitalization to Book Value Ratio Aeterna Zentaris (CSCI)